Molecular Biomedicine - Virtual Issue: Tumor Immunotherapy and Targeted Therapy
It is reported by WHO that Cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths. Almost 30% - 50% of cancer deaths could be prevented by modifying or avoiding key risk factors and implementing existing evidence-based prevention strategies. Cancer is more likely to respond to effective treatment when identified earlier, resulting in a greater probability of surviving as well as less morbidity and less expensive treatment.
This collection features papers on key topics in cancer research, and specifically focuses on Tumor Immunotherapy and Targeted Therapy in this particular issue. All articles have been published and are free to read online. Articles will undergo all of the journal's standard peer review and editorial processes outlined in its submission guidelines. (this opens in a new tab)
Development of a novel TLR8 agonist for cancer immunotherapy
Wang, Y., Yang, H., Li, H. et al.
https://link.springer.com/article/10.1186/s43556-020-00007-y (this opens in a new tab)
Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy
Yu, C., Zhang, M., Song, J. et al.
https://link.springer.com/article/10.1186/s43556-020-00013-0 (this opens in a new tab)
Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways
Wang, H., Pan, J., Barsky, L. et al.
https://link.springer.com/article/10.1186/s43556-020-00022-z (this opens in a new tab)
Cancer metabolism and intervention therapy
Zhao, H., Li, Y.
https://link.springer.com/article/10.1186/s43556-020-00012-1 (this opens in a new tab)
Targeting regulatory T cells for immunotherapy in melanoma
Huang, L., Guo, Y., Liu, S. et al.
https://link.springer.com/article/10.1186/s43556-021-00038-z (this opens in a new tab)
Progress of molecular targeted therapy for head and neck cancer in clinical aspects
Nakano, K.
https://link.springer.com/article/10.1186/s43556-021-00032-5 (this opens in a new tab)
miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ErĪ±
Ouyang, Y.X., Feng, J., Wang, Z. et al.
https://link.springer.com/article/10.1186/s43556-021-00045-0 (this opens in a new tab)
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Girisa, S., Henamayee, S., Parama, D. et al.
https://link.springer.com/article/10.1186/s43556-021-00035-2 (this opens in a new tab)
Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival
Liu, Q., Shen, H., Naguib, A. et al.
https://link.springer.com/article/10.1186/s43556-021-00053-0 (this opens in a new tab)
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Ritu, K., Kumar, P., Singh, A. et al.
https://link.springer.com/article/10.1186/s43556-021-00061-0 (this opens in a new tab)